Use of a novel low-fat hydrolyzed diet in the management of dogs with chronic enteropathy
Journal of Veterinary Internal Medicine · 02.11.2026 · 40 (6)
DOI: 10.1093/jvimsj/aalag288 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, online erschienen am 10.11.2026. Verfasst von Claudia Hernández-Anllo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Department, AniCura Ars Veterinària Veterinary Hospital, Barcelona 08034, Spain. Hauptthemen laut MEDLINE: Dog Diseases, Diet, Fat-Restricted, Intestinal Diseases. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dechra Veterinary Products SL.
Abstract (Originalsprache)
Background
Dietary management plays a central role in the diagnosis and treatment of chronic enteropathy (CE) in dogs. Although hydrolyzed–protein diets are commonly used in patients with CE, and dietary fat restriction is recommended in selected gastrointestinal disorders, the combined effect of low fat and hydrolyzed protein has not been specifically evaluated. Hypothesis/Objectives Assess clinical response and acceptability of a low-fat, hydrolyzed diet in dogs with CE. Animals Thirty-one client-owned dogs.
Methods
Prospective clinical study. Dogs were fed a commercial low-fat (2.01 g/100 kcal metabolizable energy) hydrolyzed salmon protein diet and stratified according to previous dietary history. Dogs were evaluated at baseline, 1 month, and 3 months. The primary outcome was clinical response, classified as complete response (CR), partial response (PR), or non-response (NR) based on gastrointestinal signs and the Canine Inflammatory Bowel Disease Activity Index (CIBDAI) score. Dogs with CR or PR were considered responders. Diet acceptability was assessed.
Results
At T1, 20 of 31 (64.5%) dogs were categorized as CR, 3 of 31 (9.7%) as PR, and 8 of 31 (25.8%) as NR. Twenty-three of 31 (74.2%) dogs had a positive clinical response. The CIBDAI scores decreased significantly from T0 to T1 (P < .001). At T2, 94.4% of initial responders maintained CR. Diet acceptability was excellent in 75.0% of cases. Conclusions and clinical importance This low-fat, hydrolyzed diet had significant short- and mid-term effectiveness and was well tolerated in dogs with CE, reinforcing its potential as a treatment for food-responsive enteropathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Internal Medicine Department, AniCura Ars Veterinària Veterinary Hospital, Barcelona 08034, Spain.
- Expert Pet Nutrition, 8955 Oetwil an der Limmat, Switzerland.
ORCID-Profile: Claudia Hernández-Anllo, Luis Feo, Marta Hervera, Jordi Puig
Förderung
- Dechra Veterinary Products SL
Zitieren
APA
Hernández-Anllo, C., Feo, L., Hervera, M., & Puig, J. (2026). Use of a novel low-fat hydrolyzed diet in the management of dogs with chronic enteropathy. Journal of Veterinary Internal Medicine, 40(6). https://doi.org/10.1093/jvimsj/aalag288
Vancouver
Hernández-Anllo C, Feo L, Hervera M, Puig J. Use of a novel low-fat hydrolyzed diet in the management of dogs with chronic enteropathy. Journal of Veterinary Internal Medicine. 2026;40(6). doi:10.1093/jvimsj/aalag288
BibTeX
@article{HernndezAnllo2026,
author = {Hernández-Anllo, Claudia and Feo, Luis and Hervera, Marta and Puig, Jordi},
title = {Use of a novel low-fat hydrolyzed diet in the management of dogs with chronic enteropathy},
journal = {Journal of Veterinary Internal Medicine},
year = {2026},
volume = {40},
number = {6},
doi = {10.1093/jvimsj/aalag288}
}
EUVIMED